Mouse and Human Immunology of Mice and Not Men: Differences

Total Page:16

File Type:pdf, Size:1020Kb

Mouse and Human Immunology of Mice and Not Men: Differences Of Mice and Not Men: Differences between Mouse and Human Immunology Javier Mestas and Christopher C. W. Hughes This information is current as J Immunol 2004; 172:2731-2738; ; of September 25, 2021. doi: 10.4049/jimmunol.172.5.2731 http://www.jimmunol.org/content/172/5/2731 Downloaded from References This article cites 101 articles, 27 of which you can access for free at: http://www.jimmunol.org/content/172/5/2731.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on September 25, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2004 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. THE JOURNAL OF IMMUNOLOGY BRIEF REVIEWS Of Mice and Not Men: Differences between Mouse and Human Immunology Javier Mestas and Christopher C. W. Hughes1 Mice are the experimental tool of choice for the majority of sarily true in humans. By making such assumptions we run the immunologists and the study of their immune responses risk of overlooking aspects of human immunology that do not has yielded tremendous insight into the workings of the occur, or cannot be modeled, in mice. Included in this subset human immune system. However, as 65 million years of will be differences that may preclude a successful preclinical evolution might suggest, there are significant differences. trial in mice becoming a successful clinical trial in human. Here we outline known discrepancies in both innate and In this review our aim is not to suggest that the mouse is an adaptive immunity, including: balance of leukocyte sub- invalid model system for human biology. Clearly, with so many Downloaded from sets, defensins, Toll receptors, inducible NO synthase, the paradigms that translate well between the species, and with the NK inhibitory receptor families Ly49 and KIR, FcR, Ig relative ease with which mice can now be genetically manipu- subsets, the B cell (BLNK, Btk, and ␭5) and T cell lated, mouse models will continue to provide important infor- (ZAP70 and common ␥-chain) signaling pathway com- mation for many years to come. Rather, our aim is to sound a ␥␦ word of caution. As therapies for human diseases become ever ponents, Thy-1, T cells, cytokines and cytokine recep- http://www.jimmunol.org/ tors, Th1/Th2 differentiation, costimulatory molecule more sophisticated and specifically targeted, it becomes increas- expression and function, Ag-presenting function of endo- ingly important to understand the potential limitations of ex- thelial cells, and chemokine and chemokine receptor ex- trapolating data from mice to humans. The literature is littered with examples of therapies that work well in mice but fail to pression. We also provide examples, such as multiple scle- provide similar efficacy in humans (2–7). By focusing on some rosis and delayed-type hypersensitivity, where complex known differences between mouse and human immunology we multicomponent processes differ. Such differences should hope to spur interest in this area and encourage others to note be taken into account when using mice as preclinical mod- differences where they occur. els of human disease. The Journal of Immunology, 2004, by guest on September 25, 2021 172: 2731–2738. Structure and general characteristics ice are the mainstay of in vivo immunological ex- The overall structure of the immune system in mice and hu- perimentation and in many respects they mirror hu- mans is quite similar. As this topic has been recently reviewed in M man biology remarkably well. This conservation of depth (8), we will not go into great detail here. One difference function is reflected in recent reports on the sequencing of both worth noting is that whereas mice have significant bronchus- the human and mice genomes, which reveal that to date only associated lymphoid tissue, this is largely absent in healthy hu- 300 or so genes appear to be unique to one species or the other mans (9), possibly reflecting a higher breathable Ag load for an- (1). Despite this conservation there exist significant differences imals living so much closer to the ground. between mice and humans in immune system development, ac- The balance of lymphocytes and neutrophils in adult animals tivation, and response to challenge, in both the innate and is quite different: human blood is neutrophil rich (50–70% adaptive arms. Such differences should not be surprising as the neutrophils, 30–50% lymphocytes) whereas mouse blood has a two species diverged somewhere between 65 and 75 million strong preponderance of lymphocytes (75–90% lymphocytes, years ago, differ hugely in both size and lifespan, and have 10–25% neutrophils) (10). It is not clear what, if any, func- evolved in quite different ecological niches where widely differ- tional consequence this shift toward neutrophil-rich blood in ent pathogenic challenges need to be met—after all, most of us humans has had. do not live with our heads a half-inch off the ground. However, Tyrosine kinase receptor expression on putative hemopoietic because there are so many parallels there has been a tendency to stem cells (HSC)2 shows a reciprocal pattern, with mouse HSC Ϫ ignore differences and in many cases, perhaps, make the as- being predominantly c-kithigh, flt-3 , whereas human HSC are ϩ sumption that what is true in mice—in vivo veritas—is neces- predominantly c-kitlow, flt-3 (11). Center for Immunology and Department of Molecular Biology and Biochemistry, Uni- 1 Address correspondence and reprint requests to Dr. Christopher Hughes, Department of versity of California, Irvine, CA 92697 Molecular Biology and Biochemistry, McGaugh Hall; University of California, Irvine, CA 92697. E-mail address: cchughes@uci.edu. Received for publication November 12, 2003. Accepted for publication January 23, 2004. 2 Abbreviations used in this paper: HSC, hemopoietic stem cells; iNOS, inducible NO The costs of publication of this article were defrayed in part by the payment of page charges. synthase; ␥ , common ␥-chain; DETC, dendritic epidermal T cells; MS, multiple sclerosis; This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. c DTH, delayed-type hypersensitivity; EC, endothelial cells. Section 1734 solely to indicate this fact. Copyright © 2004 by The American Association of Immunologists, Inc. 0022-1767/04/$02.00 2732 BRIEF REVIEW Innate immunity other FcR associate with ITAM-containing signal transduction One of the first lines of defense in higher organisms, and often subunits (22). the only defense in lower animals, is the growing family of an- In addition to differences in FcR there are well-known dif- timicrobial peptides, and in particular the defensins. These are ferences in expression of Ig isotypes between mice and humans, important in mucosal defense in the gut and in epithelial de- and direct correlations between subtypes within classes in each fense in skin and elsewhere (12, 13). Neutrophils are a rich species are hard to make. Mice make IgA, IgD, IgE, IgM, and source of leukocyte defensins in humans, but defensins are not four subtypes of IgG: IgG1, IgG2a, IgG2b, and IgG3. Interest- expressed by neutrophils in mice (14). In contrast, Paneth cells, ingly, in the C57BL/6, C57BL/10, SJL, and NOD strains of which are present in the crypts of the small intestine, express mice there is no expression of IgG2a, instead these mice express Ͼ20 defensins (cryptdins) in mice but only two in human, the novel IgG2c (23). Humans in contrast express two subtypes likely reflecting different evolutionary pressures related to mi- of IgA—IgA1 and IgA2—along with single forms of IgD, IgE, croorganism exposure through food intake. There are also dif- and IgM. In humans there are also four subtypes of IgG: IgG1, ferences in processing of defensins (Table I). IgG2, IgG3, and IgG4; however, these are not direct homo- The last few years have seen a renewed focus on the field of logues of the mouse proteins. While different subtypes have dif- innate immunology, spurred in large part by identification of fering abilities to bind FcR or fix complement, the differences the Toll-like family of receptors—the TLRs (15). This field is between mice and humans are not considered significant. In still relatively young and so far a limited number of differences contrast, there are differences in class switching: in mice, IL-4 have been noted between mice and humans (Table I). induces IgG1 and IgE, whereas in humans, IL-4 induces Downloaded from There has been considerable controversy as to whether hu- switching to IgG4 and IgE. In contrast, IL-13 has no effect on man macrophages express NO. Expression of functional induc- mouse B cells but induces switching to IgE in humans (24). ible NO synthase (iNOS; NOS2) in mouse macrophages has There are some interesting differences in B cell development been clearly demonstrated and iNOS mRNA is readily induced that relate to the roles of several signaling molecules. BLNK (Src by IFN-␥ and LPS (16). However, these same inflammatory homology-2 domain containing leukocyte-specific phospho- http://www.jimmunol.org/ mediators have failed to show consistent effects on human mac- protein-65) is an adapter protein that is rapidly phosphorylated rophages, hence the confusion.
Recommended publications
  • Gene Expression Polarization
    Transcriptional Profiling of the Human Monocyte-to-Macrophage Differentiation and Polarization: New Molecules and Patterns of Gene Expression This information is current as of September 27, 2021. Fernando O. Martinez, Siamon Gordon, Massimo Locati and Alberto Mantovani J Immunol 2006; 177:7303-7311; ; doi: 10.4049/jimmunol.177.10.7303 http://www.jimmunol.org/content/177/10/7303 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2006/11/03/177.10.7303.DC1 Material http://www.jimmunol.org/ References This article cites 61 articles, 22 of which you can access for free at: http://www.jimmunol.org/content/177/10/7303.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on September 27, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2006 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Transcriptional Profiling of the Human Monocyte-to-Macrophage Differentiation and Polarization: New Molecules and Patterns of Gene Expression1 Fernando O.
    [Show full text]
  • Cellular and Plasma Proteomic Determinants of COVID-19 and Non-COVID-19 Pulmonary Diseases Relative to Healthy Aging
    RESOURCE https://doi.org/10.1038/s43587-021-00067-x Cellular and plasma proteomic determinants of COVID-19 and non-COVID-19 pulmonary diseases relative to healthy aging Laura Arthur1,8, Ekaterina Esaulova 1,8, Denis A. Mogilenko 1, Petr Tsurinov1,2, Samantha Burdess1, Anwesha Laha1, Rachel Presti 3, Brian Goetz4, Mark A. Watson1, Charles W. Goss5, Christina A. Gurnett6, Philip A. Mudd 7, Courtney Beers4, Jane A. O’Halloran3 and Maxim N. Artyomov1 ✉ We examine the cellular and soluble determinants of coronavirus disease 2019 (COVID-19) relative to aging by performing mass cytometry in parallel with clinical blood testing and plasma proteomic profiling of ~4,700 proteins from 71 individuals with pul- monary disease and 148 healthy donors (25–80 years old). Distinct cell populations were associated with age (GZMK+CD8+ T cells and CD25low CD4+ T cells) and with COVID-19 (TBET−EOMES− CD4+ T cells, HLA-DR+CD38+ CD8+ T cells and CD27+CD38+ B cells). A unique population of TBET+EOMES+ CD4+ T cells was associated with individuals with COVID-19 who experienced moderate, rather than severe or lethal, disease. Disease severity correlated with blood creatinine and urea nitrogen levels. Proteomics revealed a major impact of age on the disease-associated plasma signatures and highlighted the divergent contri- bution of hepatocyte and muscle secretomes to COVID-19 plasma proteins. Aging plasma was enriched in matrisome proteins and heart/aorta smooth muscle cell-specific proteins. These findings reveal age-specific and disease-specific changes associ- ated with COVID-19, and potential soluble mediators of the physiological impact of COVID-19.
    [Show full text]
  • Anti-OX40 Antibody Directly Enhances the Function of Tumor-Reactive CD8+ T Cells
    Author Manuscript Published OnlineFirst on August 1, 2019; DOI: 10.1158/1078-0432.CCR-19-1259 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 1 Anti-OX40 antibody directly enhances the function of tumor-reactive CD8+ T cells and synergizes with PI3Kβ inhibition in PTEN loss melanoma Weiyi Peng1,5*, Leila J. Williams1, Chunyu Xu1,5, Brenda Melendez1, Jodi A. McKenzie1,6, Yuan Chen1, Heather Jackson2, Kui S. Voo3, Rina M. Mbofung1,7,, Sara E. Leahey1, Jian Wang4, Greg Lizee1, Hussein A. Tawbi1, Michael A. Davies1, Axel Hoos2, James Smothers2, Roopa Srinivasan2, Elaine Paul2, Niranjan Yanamandra2* and Patrick Hwu1* 1Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. 2Oncology R&D, Immuno-Oncology and Combinations RU, GlaxoSmithKline, 1250 S. Collegeville Rd, Collegeville, PA 19426, United States 3Oncology Research for Biologics and Immunotherapy Translation Platform, The University of Texas MD Anderson Cancer Center, Houston, TX. 4Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX. 5Present address: Department of Biology and Biochemistry, University of Houston, Houston, TX. 6Present address: Eisai Inc., Woodcliff Lake, NJ. 7Present address: Merck Research Laboratories, Palo Alto, CA. Running Title: OX40 agonist-based cancer immunotherapy Keywords: OX40, PI3K, cancer immunotherapy Downloaded from clincancerres.aacrjournals.org on September 25, 2021. © 2019 American Association for Cancer Research. Author Manuscript Published OnlineFirst on August 1, 2019; DOI: 10.1158/1078-0432.CCR-19-1259 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 2 *Corresponding Authors: Patrick Hwu, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030.
    [Show full text]
  • Enhanced Monocyte Migration to CXCR3 and CCR5 Chemokines in COPD
    ERJ Express. Published on March 10, 2016 as doi: 10.1183/13993003.01642-2015 ORIGINAL ARTICLE IN PRESS | CORRECTED PROOF Enhanced monocyte migration to CXCR3 and CCR5 chemokines in COPD Claudia Costa1, Suzanne L. Traves1, Susan J. Tudhope1, Peter S. Fenwick1, Kylie B.R. Belchamber1, Richard E.K. Russell2, Peter J. Barnes1 and Louise E. Donnelly1 Affiliations: 1Airway Disease, National Heart and Lung Institute, Imperial College London, London, UK. 2Chest Clinic, King Edward King VII Hospital, Windsor, UK. Correspondence: Louise E. Donnelly, Airway Disease, National Heart and Lung Institute, Dovehouse Street, London, SW3 6LY, UK. E-mail: l.donnelly@imperial.ac.uk ABSTRACT Chronic obstructive pulmonary disease (COPD) patients exhibit chronic inflammation, both in the lung parenchyma and the airways, which is characterised by an increased infiltration of macrophages and T-lymphocytes, particularly CD8+ cells. Both cell types can express chemokine (C-X-C motif) receptor (CXCR)3 and C-C chemokine receptor 5 and the relevant chemokines for these receptors are elevated in COPD. The aim of this study was to compare chemotactic responses of lymphocytes and monocytes of nonsmokers, smokers and COPD patients towards CXCR3 ligands and chemokine (C-C motif) ligand (CCL)5. Migration of peripheral blood mononuclear cells, monocytes and lymphocytes from nonsmokers, smokers and COPD patients toward CXCR3 chemokines and CCL5 was analysed using chemotaxis assays. There was increased migration of peripheral blood mononuclear cells from COPD patients towards all chemokines studied when compared with nonsmokers and smokers. Both lymphocytes and monocytes contributed to this enhanced response, which was not explained by increased receptor expression.
    [Show full text]
  • Differentiation and Bone Resorption Role of CX3CL1/Fractalkine In
    Role of CX3CL1/Fractalkine in Osteoclast Differentiation and Bone Resorption Keiichi Koizumi, Yurika Saitoh, Takayuki Minami, Nobuhiro Takeno, Koichi Tsuneyama, Tatsuro Miyahara, This information is current as Takashi Nakayama, Hiroaki Sakurai, Yasuo Takano, Miyuki of September 29, 2021. Nishimura, Toshio Imai, Osamu Yoshie and Ikuo Saiki J Immunol published online 18 November 2009 http://www.jimmunol.org/content/early/2009/11/18/jimmuno l.0803627.citation Downloaded from Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on September 29, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published November 18, 2009, doi:10.4049/jimmunol.0803627 The Journal of Immunology Role of CX3CL1/Fractalkine in Osteoclast Differentiation and Bone Resorption1 Keiichi Koizumi,2* Yurika Saitoh,* Takayuki Minami,* Nobuhiro Takeno,* Koichi Tsuneyama,†‡ Tatsuro Miyahara,§ Takashi Nakayama,¶ Hiroaki Sakurai,*† Yasuo Takano,‡ Miyuki Nishimura,ʈ Toshio Imai,ʈ Osamu Yoshie,¶ and Ikuo Saiki*† The recruitment of osteoclast precursors toward osteoblasts and subsequent cell-cell interactions are critical for osteoclast dif- ferentiation.
    [Show full text]
  • Complementary DNA Microarray Analysis of Chemokines and Their Receptors in Allergic Rhinitis RX Zhang,1 SQ Yu,2 JZ Jiang,3 GJ Liu3
    RX Zhang, et al ORIGINAL ARTICLE Complementary DNA Microarray Analysis of Chemokines and Their Receptors in Allergic Rhinitis RX Zhang,1 SQ Yu,2 JZ Jiang,3 GJ Liu3 1 Department of Otolaryngology, Huadong Hospital, Fudan University, Shanghai, China 2 Department of Otolaryngology , Jinan General Hospital of PLA, Shandong, China 3 Department of Otolaryngology, Changhai Hospital, Second Military Medical University, Shanghai, China ■ Abstract Objective: To analyze the roles of chemokines and their receptors in the pathogenesis of allergic rhinitis by observing the complementary DNA (cDNA) expression of the chemokines and their receptors in the nasal mucosa of patients with and without allergic rhinitis, using gene chips. Methods: The total RNAs were isolated from the nasal mucosa of 20 allergic rhinitis patients and purifi ed to messenger RNAs, and then reversely transcribed to cDNAs and incorporated with samples of fl uorescence-labeled with Cy5-dUPT (rhinitis patient samples) or Cy3- dUTP (control samples of nonallergic nasal mucosa). Thirty-nine cDNAs of chemokines and their receptors were latticed into expression profi le chips, which were hybridized with probes and then scanned with the computer to study gene expression according to the different fl uorescence intensities. Results: The cDNAs of the following chemokines were upregulated: CCL1, CCL2, CCL5, CCL7, CCL8, CCL11, CCL13, CCL14, CCL17, CCL18, CCL19, CCL24, and CX3CL1 in most of the allergic rhinitis sample chips. CCR2, CCR3, CCR4, CCR5, CCR8 and CX3CR1 were the highly expressed receptor genes. Low expression of CXCL4 was found in these tissues. Conclusion: The T helper cell (TH) immune system is not well regulated in allergic rhinitis.
    [Show full text]
  • Anti-CCL13 / MCP4 Antibody (Biotin) (ARG65993)
    Product datasheet info@arigobio.com ARG65993 Package: 50 μg anti-CCL13 / MCP4 antibody (Biotin) Store at: 4°C Summary Product Description Biotin-conjugated Goat Polyclonal antibody recognizes CCL13 / MCP4 Tested Reactivity Hu Tested Application ELISA, WB Host Goat Clonality Polyclonal Isotype IgG Target Name CCL13 / MCP4 Antigen Species Human Immunogen E. coli derived recombinant Human CCL13 / MCP4. (QPDALNVPST CCFTFSSKKI SLQRLKSYVI TTSRCPQKAV IFRTKLGKEI CADPKEKWVQ NYMKHLGRKA HTLKT) Conjugation Biotin Alternate Names SCYA13; C-C motif chemokine 13; Monocyte chemotactic protein 4; Small-inducible cytokine A13; CKb10; SCYL1; Monocyte chemoattractant protein 4; MCP-4; NCC-1; NCC1; CK-beta-10 Application Instructions Application table Application Dilution ELISA Direct: 0.25 - 1.0 µg/ml Sandwich: 0.25 - 1.0 µg/ml with ARG65992 as a capture antibody WB 0.1 - 0.2 µg/ml Application Note * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. Calculated Mw 11 kDa Properties Form Liquid Purification Purified by affinity chromatography. Buffer PBS (pH 7.2) Concentration 1 mg/ml Storage instruction Aliquot and store in the dark at 2-8°C. Keep protected from prolonged exposure to light. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use. Note For laboratory research only, not for drug, diagnostic or other use. www.arigobio.com 1/2 Bioinformation Database links GeneID: 6357 Human Swiss-port # Q99616 Human Gene Symbol CCL13 Gene Full Name chemokine (C-C motif) ligand 13 Background This antimicrobial gene is one of several Cys-Cys (CC) cytokine genes clustered on the q-arm of chromosome 17.
    [Show full text]
  • Ccl9 Induced by Tgf-Β Signaling in Myeloid Cells Enhances Tumor Cell Survival in the Premetastatic Lung
    CCL9 INDUCED BY TGF-β SIGNALING IN MYELOID CELLS ENHANCES TUMOR CELL SURVIVAL IN THE PREMETASTATIC LUNG by Hangyi Yan A dissertation submitted to Johns Hopkins University in conformity with the requirements for the degree of Doctor of Philosophy Baltimore, Maryland March, 2015 ABSTRACT The majority of cancer patients die from metastasis. To achieve metastasis, tumor cells must first survive and then proliferate to form colonies. Compelling data have shown the indispensable participation of host microenvironment for metastasis. Bone marrow derived myeloid cells sculpt a tumor-promoting microenvironment in the premetastatic organs prior to tumor cell arrival. However, the molecular mechanisms for this “seed and soil” hypothesis are unclear. Here we report that CCL9 was significantly produced and secreted by Gr-1+CD11b+ cells when co-cultured with tumor cells, and in the premetastatic lung. CCL9 knockdown (KD) in myeloid cells decreased metastasis, and this process signaled through its sole receptor CCR1. Overexpression of CCR1 lost the metastasis-promoting function in the context of CCL9 KD. CCL9 enhanced tumor cell survival in the premetastatic organs. The underlying molecular mechanisms included activation of cell survival factors phosphorylated AKT and BCL-2, as well as inhibition of Poly (ADP-ribose) polymerase (PARP)-dependent apoptosis pathway. Additionally, CCL9/CCR1 had autocrine effects, which enhanced CCL9 secretion and the survival of Gr-1+CD11b+ cells. We found that CCL9 was a key effector of myeloid transforming growth factor β (TGF-β) pathway that promotes metastasis. Decreased metastasis in mice with myeloid specific TGF-β receptor II deletion (Tgfbr2MyeKO) correlated with lower CCL9 expression in TGF-β deficient myeloid cells.
    [Show full text]
  • Differential Expression of Interferon-Γ and Chemokine Genes
    Differential expression of interferon-γ and chemokine genes distinguishes Rasmussen encephalitis from cortical dysplasia and provides evidence for an early Th1 immune response Owens et al. Owens et al. Journal of Neuroinflammation 2013, 10:56 http://www.jneuroinflammation.com/content/10/1/56 Owens et al. Journal of Neuroinflammation 2013, 10:56 JOURNAL OF http://www.jneuroinflammation.com/content/10/1/56 NEUROINFLAMMATION RESEARCH Open Access Differential expression of interferon-γ and chemokine genes distinguishes Rasmussen encephalitis from cortical dysplasia and provides evidence for an early Th1 immune response Geoffrey C Owens1,7*, My N Huynh1, Julia W Chang1, David L McArthur1, Michelle J Hickey2, Harry V Vinters2,3, Gary W Mathern1,4,5,6† and Carol A Kruse1,6† Abstract Background: Rasmussen encephalitis (RE) is a rare complex inflammatory disease, primarily seen in young children, that is characterized by severe partial seizures and brain atrophy. Surgery is currently the only effective treatment option. To identify genes specifically associated with the immunopathology in RE, RNA transcripts of genes involved in inflammation and autoimmunity were measured in brain tissue from RE surgeries and compared with those in surgical specimens of cortical dysplasia (CD), a major cause of intractable pediatric epilepsy. Methods: Quantitative polymerase chain reactions measured the relative expression of 84 genes related to inflammation and autoimmunity in 12 RE specimens and in the reference group of 12 CD surgical specimens. Data were analyzed by consensus clustering using the entire dataset, and by pairwise comparison of gene expression levels between the RE and CD cohorts using the Harrell-Davis distribution-free quantile estimator method.
    [Show full text]
  • Neutrophil Chemoattractant Receptors in Health and Disease: Double-Edged Swords
    Cellular & Molecular Immunology www.nature.com/cmi REVIEW ARTICLE Neutrophil chemoattractant receptors in health and disease: double-edged swords Mieke Metzemaekers1, Mieke Gouwy1 and Paul Proost 1 Neutrophils are frontline cells of the innate immune system. These effector leukocytes are equipped with intriguing antimicrobial machinery and consequently display high cytotoxic potential. Accurate neutrophil recruitment is essential to combat microbes and to restore homeostasis, for inflammation modulation and resolution, wound healing and tissue repair. After fulfilling the appropriate effector functions, however, dampening neutrophil activation and infiltration is crucial to prevent damage to the host. In humans, chemoattractant molecules can be categorized into four biochemical families, i.e., chemotactic lipids, formyl peptides, complement anaphylatoxins and chemokines. They are critically involved in the tight regulation of neutrophil bone marrow storage and egress and in spatial and temporal neutrophil trafficking between organs. Chemoattractants function by activating dedicated heptahelical G protein-coupled receptors (GPCRs). In addition, emerging evidence suggests an important role for atypical chemoattractant receptors (ACKRs) that do not couple to G proteins in fine-tuning neutrophil migratory and functional responses. The expression levels of chemoattractant receptors are dependent on the level of neutrophil maturation and state of activation, with a pivotal modulatory role for the (inflammatory) environment. Here, we provide an overview
    [Show full text]
  • Original Article Tocilizumab Infusion Therapy Normalizes Inflammation in Sporadic ALS Patients
    Am J Neurodegener Dis 2013;2(2):129-139 www.AJND.us /ISSN:2165-591X/AJND1304002 Original Article Tocilizumab infusion therapy normalizes inflammation in sporadic ALS patients Milan Fiala1, Mathew T Mizwicki1, Rachel Weitzman1, Larry Magpantay2, Norihiro Nishimoto3 1Department of Surgery, David Geffen School of Medicine at UCLA, 100 UCLA Medical Plaza, Suite 220, Los Angeles, CA 90095-6970, USA; 2Department of Obstetrics and Gynecology, David Geffen School of Medicine at UCLA, Los Angeles, 650 Charles E. Young Drive, Los Angeles, CA, 90095-1735, USA; 3Department of Molecular Regulation for Intractable Diseases, Institute of Medical Sciences, Tokyo Medical University, Minamisenba, Chuo- ku, Osaka, 542-0081, Japan Received April 8 2013; Accepted May 19 2013; Epub June 21, 2013; Published July 1, 2013 Abstract: Patients with sporadic amyotrophic lateral sclerosis (sALS) show inflammation in the spinal cord and pe- ripheral blood. The inflammation is driven by stimulation of macrophages by aggregated superoxide dismutase 1 (SOD1) through caspase1, interleukin 1 (IL1), IL6 and chemokine signaling. Inflammatory gene activation is inhibit- ed in vitro by tocilizumab, a humanized antibody to IL6 receptor (IL6R). Tocilizumab inhibits global interleukin-6 (IL6) signaling, a key mechanism in chronic rheumatoid disorders. Here we studied in vivo baseline inflammatory gene transcription in peripheral blood mononuclear cells (PBMCs) of 10 sALS patients, and the effects of tocilizumab (ActemraR) infusions. At baseline, one half of ALS subjects had strong inflammatory activation (Group 1) (8 genes up regulated >4-fold, P<0.05 vs. controls) and the other half (Group 2) had weak activation. All patients showed greater than four-fold up regulation of MMP1, CCL7, CCL13 and CCL24.
    [Show full text]
  • Bioinformatics Identification of CCL8/21 As Potential Prognostic
    Bioscience Reports (2020) 40 BSR20202042 https://doi.org/10.1042/BSR20202042 Research Article Bioinformatics identification of CCL8/21 as potential prognostic biomarkers in breast cancer microenvironment 1,* 2,* 3 4 5 1 Bowen Chen , Shuyuan Zhang ,QiuyuLi, Shiting Wu ,HanHe and Jinbo Huang Downloaded from http://portlandpress.com/bioscirep/article-pdf/40/11/BSR20202042/897847/bsr-2020-2042.pdf by guest on 28 September 2021 1Department of Breast Disease, Maoming People’s Hospital, Maoming 525000, China; 2Department of Clinical Laboratory, Maoming People’s Hospital, Maoming 525000, China; 3Department of Emergency, Maoming People’s Hospital, Maoming 525000, China; 4Department of Oncology, Maoming People’s Hospital, Maoming 525000, China; 5Department of Medical Imaging, Maoming People’s Hospital, Maoming 525000, China Correspondence: Shuyuan Zhang (zsyuan2020@gmail.com) Background: Breast cancer (BC) is the most common malignancy among females world- wide. The tumor microenvironment usually prevents effective lymphocyte activation and infiltration, and suppresses infiltrating effector cells, leading to a failure of the host toreject the tumor. CC chemokines play a significant role in inflammation and infection. Methods: In our study, we analyzed the expression and survival data of CC chemokines in patients with BC using several bioinformatics analyses tools. Results: The mRNA expression of CCL2/3/4/5/7/8/11/17/19/20/22 was remark- ably increased while CCL14/21/23/28 was significantly down-regulated in BC tis- sues compared with normal tissues. Methylation could down-regulate expression of CCL2/5/15/17/19/20/22/23/24/25/26/27 in BC. Low expression of CCL3/4/23 was found to be associated with drug resistance in BC.
    [Show full text]